HuGE Literature Finder
Records 1-5
|
Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes.
Pharmacogenomics 2016 Feb . Schirmer Jan Henrik, Bremer Jan Phillip, Moosig Frank, Holle Julia Ulrike, Lamprecht Peter, Wieczorek Stefan, Haenisch Sierk, Cascorbi Ingo |
|
CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.
British journal of cancer 2013 Nov 109 (11): 2803-9. Yamamoto N, Murakami H, Hayashi H, Fujisaka Y, Hirashima T, Takeda K, Satouchi M, Miyoshi K, Akinaga S, Takahashi T, Nakagawa |
|
The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013 Jun 24 (6): 1653-9. Yamamoto N, Murakami H, Nishina T, Hirashima T, Sugio K, Muro K, Takahashi T, Naito T, Yasui H, Akinaga S, Koh Y, Boku |
|
Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.
Journal of human genetics 2009 Oct 54 (10): 564-71. Low Siew-Kee, Kiyotani Kazuma, Mushiroda Taisei, Daigo Yataro, Nakamura Yusuke, Zembutsu Hitos |
|
Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days.
Cancer science 2005 Oct 96 (10): 721-8. Yamada Yasuhide, Yamamoto Noboru, Shimoyama Tatsu, Horiike Atsushi, Fujisaka Yasuhito, Takayama Kyoko, Sakamoto Terumi, Nishioka Yuki, Yasuda Sanae, Tamura Tomohi |
- Page last reviewed:Oct 1, 2020
- Page last updated:Sep 23, 2021
- Content source: